Geode Capital Management
ARTV

Geode Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Geode Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.43M Buy
353,845
+252,150
+248% +$2.3M ﹤0.01% 3060
2026
Q1 		$655K Buy
101,695
+578
+0.6% +$2.86K ﹤0.01% 3492
2025
Q4 		$434K Sell
101,117
-9,779
-9% -$36.9K ﹤0.01% 3637
2025
Q3 		$319K Sell
110,896
-48,145
-30% -$129K ﹤0.01% 3773
2025
Q2 		$240K Sell
159,041
-251,416
-61% -$528K ﹤0.01% 3813
2025
Q1 		$1.23M Buy
410,457
+94,699
+30% +$511K ﹤0.01% 3231
2024
Q4 		$3.18M Buy
315,758
+6,828
+2% +$82K ﹤0.01% 2959
2024
Q3 		$4.77M Buy
+308,930
New +$3.58M ﹤0.01% 2781

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Geode Capital Management's ARTV Position: Q2 2026 in Review

Geode Capital Management increased its Artiva Biotherapeutics (ARTV) stake by 248% in Q2 2026, buying an estimated $2.3M and bringing the position to 353,845 shares worth $3.43M. The position accounts for ﹤0.01% of the portfolio, ranked #3060.

Geode Capital Management first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.77M in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Geode Capital Management held 353,845 shares of Artiva Biotherapeutics worth $3.43M as of Q2 2026.
  • Geode Capital Management bought 252,150 Artiva Biotherapeutics shares in Q2 2026, an estimated $2.3M.
  • Artiva Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #3060 holding.
  • Geode Capital Management first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • Geode Capital Management's Artiva Biotherapeutics position peaked at $4.77M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.